XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue recognition
 3 Months Ended
Mar. 30, 2024
Revenue from Contract with Customer [Abstract]  
Revenue recognition Revenue recognition
Our policies for recognizing sales have not changed from those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the legal entity from which the sale originated.
As previously discussed in Note 1. Organization, SonicOne revenue was reclassified from Restorative Therapies to Surgical Solutions on a prospective and retrospective basis as its capabilities to remove devitalized or necrotic tissue and fiber deposits more closely aligns with Surgical Solutions’ soft tissue management. SonicOne revenue reclassified for the three months ended April 1, 2023 totaled $1,712 and $65 for the U.S. and International reporting segments, respectively. The Company had product sales to one customer totaling $13,143 in the U.S. segment during the three months ended March 30, 2024, representing 10.2% of total net sales. The following table presents the Company’s net sales disaggregated by major business within each segment as follows:
Three Months Ended
March 30, 2024April 1, 2023
U.S.
Pain Treatments
$50,637 $40,995 
Restorative Therapies25,304 30,776 
Surgical Solutions38,340 32,207 
Total U.S. net sales114,281 103,978 
International
Pain Treatments
6,052 5,331 
Restorative Therapies5,170 5,549 
Surgical Solutions3,954 4,201 
Total International net sales15,176 15,081 
Total net sales$129,457 $119,059